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Hereditary tyrosinemia Type 1 (HT-1) is a rare metabolic disease where the enzyme
catalyzing the final step of tyrosine breakdown is defect, leading to accumulation of
toxic metabolites. Nitisinone inhibits the degradation of tyrosine and thereby the
production of harmful metabolites, however, the concentration of tyrosine also
increases. We investigated the relationship between plasma tyrosine concentrations
and cognitive functions and how tyrosine levels affected enzyme activities of human
tyrosine hydroxylase (TH) and tryptophan hydroxylase 2 (TPH2). Eight Norwegian
children between 6 and 18 years with HT-1 were assessed using questionnaires mea-
suring Attention Deficit Hyperactivity Disorder (ADHD)-symptoms and executive
functioning. Recent and past levels of tyrosine were measured and the enzyme activi-
ties of TH and TPH2 were studied at conditions replicating normal and pathological
tyrosine concentrations. We observed a significant positive correlation between
mean tyrosine levels and inattention symptoms. While TH exhibited prominent sub-
strate inhibition kinetics, TPH2 activity also decreased at elevated tyrosine levels.
Inhibition of both enzymes may impair syntheses of dopamine, noradrenaline, and
serotonin in brain tissue. Inattention in treated HT-1 patients may be related to
decreased production of these monoamines. Our results support recommendations
of strict guidelines on plasma tyrosine levels in HT-1. ADHD-related deficits, particu-
larly inattention, should be monitored in HT-1 patients to determine whether inter-
vention is necessary.
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1 | INTRODUCTION
Many metabolic diseases influence brain function and are associated
with psychiatric symptoms and neuropsychiatric disorders (including
autism-spectrum disorders, ADHD and psychotic disorders). ADHD is
a common neurodevelopmental disorder with symptoms of either
hyperactivity/impulsivity, or inattention, or both (American Psychiatric
Association, 2013). ADHD has high rates of comorbidity with psychi-
atric or somatic disorders, possibly reflecting shared pathophysiologi-
cal mechanisms (Instanes, Klungsoyr, Halmoy, Fasmer, & Haavik,
2018). Knowledge about the relationship between neurometabolic
disorders (NMDs) and symptoms of ADHD may provide insight into
the etiology of ADHD, as well as improve the clinical management of
patients with such conditions. As symptoms of ADHD have been
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linked to low dopamine levels in prefrontal cortex, studies of meta-
bolic disorders influencing the dopamine system have been of particu-
lar interest. Similarities in neurodevelopmental functioning have been
found, for example, between treated phenylketonuria and ADHD
(Stevenson & McNaughton, 2013), but also between ADHD and
hereditary tyrosinemia Type 1 (HT-1; OMIM 276700; Pohorecka
et al., 2012).
Hereditary tyrosinemia Type 1 is an autosomal recessive disease
caused by loss-of-function mutations in the gene encoding
fumarylacetoacetate hydrolase (FAH; EC 3.7.1.2), the last enzyme in
the tyrosine degradation pathway. The incidence in most of the world
is estimated to be 1 in 100–120,000 live births. In Norway, incidence
is approx. 1 in 74,800 live births (Bliksrud, Brodtkorb, Backe,
Woldseth, & Rootwelt, 2012). Lack of functional FAH leads to accu-
mulation of metabolites like fumarylacetoacetate and succinylacetone,
which causes organ damage, including progressive liver disease with
pronounced cirrhosis, regeneration and secondary renal tubular dys-
function. Individuals with the most acute form present with severe
liver failure within weeks after birth, whereas patients with the
chronic form may present with hypophosphatemic rickets, cirrhosis,
and hepatocellular carcinoma (HCC; De Baulny, 2014; Trahms, 2001).
Untreated, these patients die from cirrhosis or HCC at a young age.
Following the diagnosis, individuals with HT-1 are treated with
the drug nitisinone, combined with a protein-restricted diet.
Nitisinone (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
(NTBC)) reversibly inhibits the degradation of tyrosine at an earlier
step by acting on 4-hydroxyphenylpyruvate dioxygenase (HPPD), thus
protecting the liver against the carcinogenic metabolites, but the tyro-
sine level remains elevated. Nitisinone has dramatically improved the
prognosis of HT-1 (G. Mitchell, 2015), especially if treatment is started
early, but it is unclear if the phenylalanine and tyrosine-reduced diet is
sufficient to reduce plasma tyrosine to levels that prevent cognitive
deficits (Bendadi et al., 2014). In patients with tyrosinemia Type III
with similar concentrations of tyrosine as treated HT-1 patients, and
in tyrosinemia Type II, with even higher levels of tyrosine,
neurocognitive difficulties are prominent (G. A. Mitchell, Grompe,
Lambert, & Tanguay, 2001; Natt, Kida, Odievre, Di Rocco, & Scherer,
1992). This is in accordance with studies showing learning difficulties
(Masurel-Paulet et al., 2008), lower IQ (Thimm et al., 2012), sub-
optimal motor function (Thimm et al., 2012), difficulties with social
cognition (van Ginkel et al., 2016), inattentiveness (Pohorecka et al.,
2012), and difficulties with working memory (van Ginkel et al., 2016)
among treated HT-1 patients. See Figure 1 for information about the
catabolic pathways for the different types of tyrosinemia and
nitisinone.
Several mechanisms have been suggested for the neu-
rodevelopmental problems observed in HT-1, including direct toxic
effect of high tyrosine, negative sequelae of severe liver disease
before treatment, impaired influx of amino acids into the brain,
decreased serotonin in the central nervous system, low levels of phe-
nylalanine in blood and direct negative effects of nitisione (van Ginkel,
Jahja, Huijbregts, & van Spronsen, 2017). In addition, a possible rela-
tionship between high tyrosine levels and high dopamine has been
suggested, as tyrosine is a precursor for dopamine (van Ginkel et al.,
2017). Walker, Pitkanen, Rahman, and Barrington (2018) reported
underperformance on neurocognitive tests in three patients with HT-
1, with highest plasma tyrosine levels in the patient struggling most
on the neurocognitive tests.
ADHD-symptoms may be related to decreased function of the
catecholamine transmitters dopamine and noradrenaline in prefrontal
cortex (Borodovitsyna, Flamini, & Chandler, 2017; Volkow et al.,
2009). Biosynthesis of catecholamines relies partly on phenylalanine
that is converted into tyrosine by the liver enzyme phenylalanine
hydroxylase (PAH, EC 1.14.16.1). Thus, in classical PKU, mutations in
the PAH gene diminish PAH activity, resulting in low levels of tyro-
sine, which leads to decreased dopamine levels in PKU (Antshel &
Waisbren, 2003a). Although dietary treatment could prevent severe
cognitive impairment, residual symptoms have been reported
(Stevenson & McNaughton, 2013). This is supported by a study show-
ing that 26% of children with treated PKU used central stimulants for
attentional dysfunction, compared to 6.5% in a group with Type 1 dia-
betes mellitus (Arnold, Vladutiu, Orlowski, Blakely, & DeLuca, 2004).
van Ginkel et al. (2017) have argued that nitisinone-treated HT-1 and
PKU display similar neurodevelopmental characteristics as well. How-
ever, the proposed explanations for those features have been strik-
ingly different, as treated HT-1 has been suggested to feature
elevated dopamine levels in the prefrontal cortex. Understanding the
relationship between HT-1 with ADHD and PKU could bring new
insights into the underlying biological mechanisms behind HT-1, carry-
ing the potential for improved treatment for the cognitive difficulties
observed in this group.
Transport of large neutral amino acids across the blood–brain bar-
rier (BBB) is mediated by endothelial L-type amino acid transporter
1 (LAT1, SLC7A5) in a heterodimeric complex with heavy chain 4F2
antigen (Yan, Zhao, Lei, & Zhou, 2019). The transport of amino acids
F IGURE 1 The tyrosine degradation pathway. The first, second
and last steps are inhibited in tyrosinemia type 2, 3 and 1,
respectively. In tyrosinemia type 1, fumarylacetoacetate and
maleylacetoacetate are metabolised further to succinylacetone.
Nitisinone is inhibiting 4HPPD, protecting against toxic metabolites.
TAT, tyrosine aminotransferase; 4HPPD, 4-hydroxyphenylpyruvate
dioxygenase; FAA, fumarylacetoacetase
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like leucine, isoleucine, phenylalanine, tyrosine, tryptophan, and
methionine is therefore mediated by the same transporter system into
or out of the brain, and is hence mutually competitive, depending on
their affinity for LAT1 and their concentration in plasma or brain tis-
sue, respectively (de Groot et al., 2013). Hyperaminoacidemias such
as PKU and HT-1 are expected to affect the transport flux of amino
acids into the brain. Thus, high circulating levels of phenylalanine in
PKU will compete out other LAT1 transported amino acids such as
tyrosine and tryptophan, lowering brain protein synthesis, as well as
compromising biosynthesis of catecholamines and serotonin. This may
lead to cognitive deficits (Yano, Moseley, Fu, & Azen, 2016). For
nitisinone treated HT-1, high plasma levels of tyrosine, is expected to
decrease the flux of other LAT1 transported amino acids into the
brain—such as tryptophan—which may affect serotonin synthesis.
Conventionally, the high levels of tyrosine have been suspected to
increase catecholamine synthesis in the brain (van Ginkel et al., 2017).
Here we present a new hypothesis for the cognitive difficulties
observed in HT-1, arguing that high levels of tyrosine may impair the
synthesis of dopamine and norepinephrine, due to the pronounced
substrate inhibition kinetics of tyrosine hydroxylase (TH, EC
1.14.16.2), the rate-limiting enzyme of catecholamine synthesis.
Dopamine is synthesized from tyrosine by TH and aromatic amino
acid decarboxylase (AAAD, EC 4.1.1.26) prior to vesicular transport
and storage (Figure 2), whereas norepinephrine is synthesized from
dopamine by dopamine β-hydroxylase within these synaptic vesicles.
TH hydroxylates tyrosine in an iron(II) dependent reaction, using the
cosubstrate tetrahydrobiopterin (BH4) and molecular oxygen. TH
shows substrate inhibition kinetics for tyrosine even at physiological
concentrations (Kumer & Vrana, 1996; Quinsey, Luong, & Dickson,
1998). Under normal conditions, substrate inhibition can be beneficial,
as it has been suggested to stabilize the synthesis of catecholamines
against fluctuations caused by variable dietary intake of tyrosine
(Reed, Lieb, & Nijhout, 2010). An implication of this kinetic feature of
TH is that the high levels of tyrosine in HT-1 may lead to substantial
inhibition of the enzyme and thus a decrease of dopamine synthesis.
We therefore hypothesized that both high and low levels of tyrosine
may lead to impaired synthesis of catecholamines, which could explain
the similarities found between PKU and HT-1.
The homologues enzyme of TH and PAH, tryptophan hydroxylase,
catalyzes the first and rate-limiting step of serotonin synthesis
(Figure 2). Low serotonin levels have also been reported in HT-1
(Thimm et al., 2011). In addition to the expected inhibitory effect of
tyrosine on tryptophan transport into the brain, we hypothesized that
high levels of tyrosine could also inhibit the activity of human trypto-
phan hydroxylase 2 (TPH2, EC 1.14.16.4), the rate-limiting enzyme of
brain serotonin synthesis.
On this background, we aimed to measure core symptoms of
ADHD in HT-1 and relate this to plasma levels of tyrosine. Especially
inattention problems have been frequently reported by parents of
children with treated PKU (using the ADHD RS-IV; Mooney, Prasad, &
Shaffer, 2013), and a correlation between inattention scores and
levels of phenylalanine in serum has been found in tetrahydrobioptein
(sapropterin) responders (Wyrwich et al., 2015). Because of the pro-
posed similarities between PKU and HT-1, inattention was also the
main focus of this study. However, Barkley (2003) pointed out that
although ADHD has been viewed as a disorder of primarily inattention
and hyperactive–impulsive behavior, newer theories characterized
deficits in executive functioning as essential to the disorder. Executive
function problems are found to be associated with high levels of phe-
nylalanine (Bilder et al., 2016). Because of the possible shared cogni-
tive/behavioral phenotypes in PKU and ADHD, executive functioning
is therefore also of particular interest when investigating HT-1.
In this study, we investigated the relationship between elevated
plasma levels of tyrosine found in treated HT-1 patients and core
symptoms of ADHD, namely, inattention, hyperactivity, and executive
functioning deficits. We also assessed the effect of physiological and
pathophysiological levels of tyrosine on the in vitro activity of human
TH1, the major human TH isoform, as well as human TPH2, expressed
in brain serotonergic neurons.
We asked the following questions:
1. Are ADHD-symptoms overrepresented in HT-1 patients in
Norway?
F IGURE 2 Tyrosine and tryptophan transport through the blood–
brain barrier. The figure illustrates the impact of high plasma levels of
tyrosine (Tyr) on its own transport into the brain and into target cells,
as well as on transport of tryptophan (Trp). Transport of large,
uncharged amino acids across the tightly junctioned endothelial cells
of brain capillaries, a feature of the blood–brain barrier, is mediated
by the L-type amino acid transporter via a mutual competitive kinetic
mechanism. High Tyr levels will inhibit transport of Trp into and out
of the brain. Inhibition of Trp transport into brain cells, for example,
serotonergic cells by extreme high Tyr levels is also predicted.
3,4-dihydroxyphenylalanine (L-Dopa) is synthesized from Tyr by TH
and further decarboxylated by aromatic amino acid decarboxylase
(AAAD) to dopamine (DA). DA is subsequently transported and stored
in synaptic vesicles. A similar pathway is used to synthesize serotonin
(SE) from Trp, only that the first enzyme, tryptophan hydroxylase
2 (TPH2), mediates the hydroxylation of Trp to 5-hydroxytryptophan
(5HTrp). The possible inhibition of TH and TPH2 by high levels of Tyr
were investigated in this study
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2. Is the concentration of tyrosine in blood directly linked with the
severity of ADHD-related symptoms and executive function per-
formance in HT-1?
3. If so, could this association be explained by inhibition of TH and
caused by elevated tyrosine levels?
2 | METHODS
2.1 | Sample description
All parents to children (0–18 years) with HT-1 in Norway were given
oral and written information about the project. If children were
12 years or older, they also signed the informed consent form in addi-
tion to their parents. Project approval was granted by the Regional
Committee for Medical Research Ethics of Western Norway (IRB
00001872). Eleven out of 12 eligible children initially participated in
the project. However, to ensure sufficient sample homogeneity, only
children between 6 and 18 years (N = 10) were included in the actual
analyses. Two potential participants (2 and 3 years old) were excluded
because of their young age and one participant with epilepsy was
excluded, as epilepsy may cause cognitive difficulties in itself that are
not directly related to HT-1 (although it may be possible that the epi-
lepsy developed secondarily to HT-1 or its treatment). Diagnoses had
been given biochemically with detection of the pathognomonic
succinylacetone and confirmed using DNA sequencing with detection
of known disease mutations.
2.2 | Instruments
Questionnaires were filled in by parents to rate symptoms of ADHD
and executive functioning. Levels of tyrosine from 2009 to 2016 and
during 2017 were calculated separately. This was done to study the
mean level from the year questionnaires were filled in (2017), in addi-
tion to long-term levels. Effects of increasing tyrosine concentrations
on TH and TPH2 were studied in in vitro experiments.
Parent forms of ADHD Rating Scale-IV (ADHD RS-IV; DuPaul
et al., 1998) and behavior rating inventory of executive functioning
(BRIEF; Gioia, Isquith, Guy, & Kenworthy, 2000) were used to mea-
sure inattention, hyperactivity, and executive functioning.
ADHD RS-IV is an 18-item rating scale that assesses ADHD-
symptoms in children on a four-point Likert scale (0 = never or rarely,
1 = sometimes, 2 = often, 3 = very often). The instrument is divided
into two subscales (hyperactive/impulsive and inattention symptoms)
and is designed to be similar to the ADHD-symptoms found in the
“Diagnostic and Statistical Manual of Mental Disorders” (American
Psychiatric Association, 2000). It has shown good psychometric prop-
erties (DuPaul et al., 1998). In Norway, there is a lack of official norms
(Kornør & Bøe, 2011), but in Denmark, it has been standardized on
approximately 600 children (Poulsen, Jørgensen, Dalsgaard, &
Bilenberg, 2009). Both norms from the United States and from Den-
mark were used, with very similar results. A study from the United
States has also supported the reliability and validity of ADHD RS-IV in
PKU (Wyrwich et al., 2015).
The Norwegian version of BRIEF has shown good psychometric
properties (Sørensen & Hysing, 2014). The parent version of BRIEF
consists of 86 items that measure metacognition (Initiate, Plan/Orga-
nize, Working Memory, Organization of Materials and Monitor) and
Behavioral Regulation (Emotional Control, Shift, Inhibit). Responses
are given on a Likert scale indicating if the behavior of a child is
“Never a problem,” “Sometimes a problem,” or “Often a problem.”
2.3 | Enzyme purification and activity assays
Human TH isoform 1 and human TPH2 were expressed in Escherichia
coli (BL21) and purified to homogeneity as described in Szigetvari
et al. (2019) and Winge et al. (2008), respectively. Enzyme activities
were measured in standard reaction mixtures (Szigetvari et al., 2019)
at 37C and were stopped after 5 min. The specific activity of TH was
assayed at tyrosine concentrations ranging from 4 to 1,400 μM, while
the concentration of tetrahydrobiopterin (BH4) was kept constant at
its estimated physiological concentration, 50 μM (Fossbakk, Kleppe,
Knappskog, Martinez, & Haavik, 2014). TPH2 activity was measured
at a substrate (tryptophan) concentration of either 20 or 60 μM, in the
presence of 0–1,000 μM tyrosine. Formation of the reaction products
L-DOPA and L-5-hydroxytryptophan, respectively, were detected via
their native fluorescence, using high-performance liquid chromatogra-
phy with fluorometric detection (Haavik & Flatmark, 1980). TH kinetic
values were fitted by nonlinear regression analysis using the
Michalies–Menten equation with substrate inhibition (Equation 1) in
Graph-Pad Prism 7.0, where v is the rate of the reaction, S is the con-
centration of substrate, Vmax the maximal rate, Km the half saturation
constant, and Ksi is the substrate inhibition constant.
v =
VmaxS
Km + S 1+ SKsi
  ð1Þ
2.4 | Statistical analyses
IBM SPSS Statistics 24 was used to perform the statistical analyses.
The relationship between ADHD-related symptoms and levels of tyro-
sine was investigated using Pearson product–moment correlation
coefficient. To check for normality, linearity, and homoscedasticity,
preliminary analyses were performed, and nonparametric statistics
(Spearman, 1904) were used when assumptions were violated. Pear-
son product–moment correlation analyses between variables from
BRIEF and ADHD RS-IV were also performed (only when significantly
correlated with tyrosine).
The relationship between inattentive symptoms and mean levels
of tyrosine in 2017 was explored while controlling for age (months) at
diagnosis. Preliminary analysis showed a violation to the assumption
of linearity, therefore non-parametric partial correlation was chosen.
A Spearman bivariate correlation was performed for all variables and
the Spearman rank correlation coefficients was added into a new file.
The row type from the Spearman (RHO) was converted to a Pearson
product–moment correlation. Partial correlation was then performed
using the newly created correlation coefficients. As we expected high
4 BARONE ET AL.
levels of tyrosine to be related to high levels of ADHD-related symp-
toms, one-tailed tests were used in all correlation analyses, except
when performing Pearson product–moment correlation between the
working memory subscale from BRIEF and the inattention scale from
ADHD RS-IV.
3 | RESULTS
Mean plasma level of tyrosine from 2009 to 2016 was 477 μmol/L
(range 358–644 μmol/L) and 623 μmol/L in 2017 (range
349–831 μmol/L). Mean age was 13.1 years (range 7–17) and mean
age at diagnosis was 13 months (range 0–30). See Table 1 for individ-
ual characterization of participants.
All T-scores were around 50 or lower (50 = mean), both on the
ADHD RS-IV (norms from Denmark and United States) and on BRIEF
(Tables 2 and 3).
We observed a significant positive correlation between inatten-
tion symptoms on ADHD RS-IV and mean tyrosine level the last
8 years (r = .707, p = .025) and in 2017 (r = .780, p = .011; Figure 3a,
b). The working memory index on BRIEF was significantly correlated
with levels of tyrosine the last 8 years (r = .659, p = .038) (Figure 4),
but not with mean level in 2017 (r = .593, p = .061). T-scores for inat-
tention and working memory were also significantly correlated
(r = .829, p = .011, two-tailed).
A strong positive correlation between levels of tyrosine in 2017
and symptoms of inattention (r = .839, p = .009) was found after con-
trolling for age (months) at diagnosis.





at 8 years (μmol/L)
Mean tyrosine,
2017 (μmol/L)
1 13–18 >12 455 ± 93 609 ± 174
2 13–18 >12 421 ± 121 684 ± 19
3 13–18 <12 393 ± 102 627 ± 18
4 13–18 >12 634 ± 114 787 ± 85
5 13–18 >12 644 ± 182 831 ± 144
6 6–12 <12 490 ± 71 652 ± 77
7 6–12 <12 417 ± 145 445 ± 93
8 6–12 >12 358 ± 82 349 ± 204
TABLE 2 ADHD RS-IV, results according to United States and
Danish norms (DN; N = 8)
Minimum Maximum Mean SD
Inattention 38 60 50.1 6.7
Inattention DN 37 61 51.3 7.8
Hyperactivity 40 68 49.9 8.7
Hyperactivity DN 38 67 50 9.4
Total 38 61 49.9 7.1
Total DN 36 60 50.5 8.1
TABLE 3 BRIEF T-scores, subscales, and indexes (N = 8)
Minimum Maximum Mean SD
Inhibition 36 60 47.0 8.9
Shifting 40 61 47.0 7.7
Emotional control 41 68 48.9 9.7
Initiate 39 63 47.4 7.1
Working memory 38 63 52.1 8.0
Plan/organize 39 63 51.1 7.8
Organization of materials 40 58 51.0 5.8
Monitor 32 49 43.1 5.7
Behavioral regulation index 40 62 47.5 8.9
Metacognition index 37 54 48.9 5.4
Global executive index 38 57 48.4 6.4
Abbreviation: BRIEF, behavior rating inventory of executive functioning.
F IGURE 3 (a) Relation between mean levels of tyrosine
(2009–2016) and levels of inattention on ADHD RS-IV. (b) Relation
between level of tyrosine in 2017 and inattention on ADHD RS-IV
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3.1 | Effect of pathological tyrosine levels on TH and
TPH2 enzyme functions
We measured the activity of purified recombinant human TH isoform
1 (TH) at tyrosine concentrations spanning the range of normal plasma
(19–119 μM, green area Figure 5a) (Gregory, Sovetts, Clow, & Scriver,
1986; Shih, 2003) and that reported for nitisinone-treated HT-1
patients (mean levels at or above 349 μM, red area Figure 5a). TH
activity was measured at intracellular relevant physiological condi-
tions, including BH4 levels corresponding to the estimated intracellular
concentration (Fossbakk et al., 2014). Maximal TH activity was
observed at around 30 μM tyrosine. Substrate inhibition of TH was
obvious even at physiological tyrosine levels. Comparing the enzyme
velocity at median normal plasma tyrosine levels to that of median
plasma level of nitisinone treated HT-1 patients, showed an 81%
reduction—alternatively, a 71–85% decrease within the 349–831 μM
tyrosine range reported from HT-1 patients under treatment
(Figure 5a), suggesting that catecholamine synthesis may be com-
promised under such conditions (Table 4).
F IGURE 4 Relation between mean plasma tyrosine
concentrations (2009–2016) and working memory index from BRIEF.
BRIEF, behavior rating inventory of executive functioning
F IGURE 5 Effect of tyrosine on TH and TPH2 activity. The activity of TH and TPH2 was assessed in the presence of different concentrations
of tyrosine ([L-Tyr], note logarithmic scale on x-axis). For assay conditions and procedures, we refer to Section 2. The green shaded area
represents the normal plasma levels of tyrosine (19–119 μM) and the red shaded area plasma tyrosine concentrations reported for nitisinone
treated HT-1 patients. (a) Shows TH activity as a function of increasing amounts of tyrosine. TH activity increases toward about 30 μM Tyr, but
decreases above this level due to substrate inhibition. (b) TPH2 activity (%, 100% without tyrosine present) measured at 20 μM (●) or 60 μM ()
tryptophan and with increasing amounts of tyrosine present in the assay. TH, tyrosine hydroxylase; TPH2, tryptophan hydroxylase 2
TABLE 4 Specific activity of human TH1 measured under
physiological conditions
Vmax (nmol min
−1 mg−1) Km (μM) Ksi (μM) R2
2,822 ± 511.1 30.61 ± 7.76 28.91 ± 7.01 0.971
Note: Vmax, Km (tyrosine concentration at half maximal rate), and Ksi
(substrate inhibition constant for tyrosine) values shown here represent
the best-fit values within 95% confidence interval ± SD. The substrate
inhibition of TH is obvious present even at physiological tyrosine levels.
There is an apparent overlap between Km and Ksi values. The explanation
for this is that the standard substrate inhibition kinetic equation employed
here cannot factor in the consequences of the orderly nature of substrate
and cofactor binding by TH during the catalytic reaction, as it can only do
the fitting for a single substrate variable.
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A decrease in serotonin levels has also been reported in HT-1
(Thimm et al., 2011). Consequently, we examined the effects of
increasing tyrosine levels on the activity of human TPH2, the rate-
limiting enzyme of brain serotonin synthesis (Figure 5b). We observed
53–60% reduction in TPH2 activity going from median normal plasma
tyrosine levels to that of median plasma levels of nitisinone-treated
HT-1 patients. The decrease in activity was more prominent with
lower tryptophan concentrations (from 46–59% to 53–64% reduction
in catalytic activity in the tyrosine range of 349–831 μM, after trypto-
phan was reduced threefold), suggesting a competitive inhibition by
tyrosine.
4 | DISCUSSION
4.1 | Summary of findings
In this study, we observed strong correlations between symptoms of
inattention and both recent and long-term plasma levels of tyrosine in
HT-1 patients receiving nitisinone medication. We also found a nega-
tive correlation between working memory and tyrosine levels. This
was expected, as the working memory scale from BRIEF and the inat-
tention scale from ASRS RS-IV were highly correlated, as also shown
in other studies, for example, in patients with PKU (Wyrwich
et al., 2015).
It has been speculated whether the high plasma tyrosine levels
found in HT-1 patients on nitisinone treatment would increase dopa-
mine synthesis in the brain (van Ginkel et al., 2017). However, our bio-
chemial studies on human TH indicated that at such extreme levels of
tyrosine, the activity of the enzyme may be reduced by substrate inhi-
bition. Thus, we hypothesize that the inhibition of TH activity also
reduces the levels of dopamine and norepinephrine in the brain.
4.2 | Shared phenotypes between ADHD,
phenylketonuria, and HT-1?
ADHD is suggested to be associated with decreased activity of dopa-
mine in prefrontal cortex (Volkow et al., 2009) and is found to be 2.5
times more prevalent in PKU than in the general population, with high
level of dimensional symptoms also in patients not fulfilling the criteria
for diagnosis (Antshel & Waisbren, 2003b). Central stimulants, such as
methylphenidate, the most common pharmacological treatment for
ADHD, inhibits the synaptic dopamine and noradrenaline trans-
porters, thereby increasing the concentration of these catecholamines
in the synapses. This reduces core symptoms in a majority of children
with ADHD (Swanson et al., 2001; Wilens & Biederman, 1992),
improves motoric functioning (Stray, Ellertsen, & Stray, 2010) and
reduces negative social behavior (Gadow, Nolan, Sprafkin, & Sverd,
1995; Gillberg et al., 1997; Hinshaw, Henker, Whalen, Erhardt, &
Dunnington, 1989). Interestingly, the neurodevelopmental problems
seen in diet-treated PKU and ADHD are very similar. In PKU, prob-
lems with executive functioning (Huijbregts, Gassio, & Campistol,
2013) and lower social skills (Jahja et al., 2016) are described, in addi-
tion to impaired motor function, working memory and attention
(summarized in a meta-analysis by Stevenson and McNaughton
(2013)). Stevenson and McNaughton have examined whether PKU
and ADHD give common phenotypes and postulated that reduced
dopamine activity in the prefrontal cortex may be responsible for cog-
nitive impairments in PKU, similar to the etiology proposed in ADHD
by Solanto (2002).
An impaired serotonin homeostasis has also been reported in
treated HT-1 (Thimm et al., 2011); this was suggested to stem from
impeded transport of tryptophan across the BBB. Similarly to the dis-
ruption of TPH activity in PKU, attributed to high phenylalanine levels,
an analogous inhibitory effect by tyrosine was speculated. Here, we
suggest that the reduced serotonin synthesis and cognitive symptoms
in HT-1 may be manifestations of the cumulative effects of decreased
brain tryptophan availability, as well as inhibition of TPH2 by the com-
peting tyrosine.
Our study provides more insight into the hitherto unexplained
similarities between cognitive difficulties found in treated HT-1,
ADHD, tyrosinemia Type 2 and 3 as well as PKU. The strong correla-
tion between recent tyrosine concentrations and levels of inattention,
and the even more robust correlation when correcting for age at diag-
nosis, support the notion that transient concentration of tyrosine
could be more relevant for levels of inattention than long-term con-
centrations, and that these effects are not directly attributed to
nitisinone itself. Garcia, de la Parra, Arias, Arredondo, and Cabello
(2017) reported a decline in IQ (mean of 16.8 IQ points) over mini-
mum 2 years in patients receiving a diagnosis before 8 months of age
(with first symptom appearing between the first and third months).
Bendadi et al. (2014) also found a decline in IQ in a group with HT-1
who were 8 months or younger when receiving the diagnosis. Inter-
estingly, in their study, the IQ and tyrosine levels were not correlated.
Furthermore, the decline in IQ values reported by Garcia et al. was
not found in children diagnosed between 8 and 47 months of age. In
contrast to prior beliefs, early brain damage has been related to
decline in IQ over the course of development, especially with rela-
tively small lesions. This was found in a study of children with unilat-
eral brain injury (mainly with pre- or perinatal infarctions), but decline
in IQ over time has also been found in children with Trisomy 21 (Carr,
1988) and Fragile X syndrome (Hagerman et al., 1989). Similarly, it
may be that early onset of HT-1 impacts the vulnerable infant brain
more or differently, compared to those presenting with symptoms
later. While it has been difficult to demonstrate a clear correlation
between IQ-scores and metabolic control, a study by Pohorecka et al.
(2012) found that attention difficulties were related to fluctuating
levels of tyrosine (in a group with IQ similar to the population mean)
and the study by Walker et al. showed higher levels of tyrosine in
patients performing poorly on neuropsychological assessment (Walker
et al., 2018). Performance on a load-dependent working memory task
also decreased with higher levels of orally administered tyrosine in
adults (van de Rest, Bloemendaal, de Heus, & Aarts, 2017). This indi-
cates that tyrosine levels may be more strongly connected to the
other cognitive problems described in this group than to IQ values.
However, in the study by Pohorecka et al., an association between
verbal IQ and inattention was found, and a meta-analysis has shown a
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nine point lower IQ in patients with ADHD than in a control group of
healthy siblings (Frazier, Demaree, & Youngstrom, 2004). Despite this,
these findings do not explain why mean IQ of patients with HT-1 in
some studies are found to be as low as 71 (Bendadi et al., 2014). In
comparison, in a study of children with early treated PKU, the mean
IQ was 91 (Griffiths, Demellweek, Fay, Robinson, & Davidson, 2000);
only nine points below the norms. If HT-1, ADHD and PKU share bio-
logical mechanisms and a common phenotype regarding ADHD-
related problems, a similar influence on IQ from the ADHD-related
symptoms could be expected in HT-1 as in PKU and ADHD. There-
fore, the very low IQ-levels found in some studies of HT-1 (and not in
others) possibly point to partly different trajectories for reduced intel-
lectual functioning in HT-1 and ADHD/PKU, and subgroups with
partly different etiology behind the cognitive difficulties in HT-1.
Accordingly, medication aiming to increase brain levels of catechol-
amines, such as inhibitors of dopamine and norepinephrine trans-
porters, may be useful in the treatment of ADHD-related difficulties
in HT-1, as also demonstrated for some of the children in this study
(data not shown). Research on biological mechanisms and possible
treatments for ADHD-related symptoms in HT-1 could provide more
refined venues for medical intervention through dietary control and
compensatory treatment.
4.3 | Executive functioning and HT-1
On the BRIEF scale, only working memory was correlated with levels
of tyrosine, and this subscale was also highly correlated with the inat-
tention subscale from ADHD RS-IV. Although that some researchers
consider problems with executive function as core deficits in ADHD,
others have argued that although such difficulties are important in
ADHD, they are neither sufficient nor necessary in all cases of ADHD
(Willcutt, Doyle, Nigg, Faraone, & Pennington, 2005).
4.4 | Decline in cognitive functioning over time?
In all but one participant, mean levels of tyrosine in 2017 were higher
than those from the 2009 to 2016 period. This may be related to the
fact that it has been discussed if recommended levels of P-tyrosine
<600 μmol should be suggested (instead of a level <500 μmol). In
2017, this was also included in guidelines (Chinsky et al., 2017). On
the other hand, if this finding could be generalized to patients with
HT-1, a possible decline in cognitive functions could be attributed to
the increased tyrosine levels. Both the decline in IQ documented in
other studies, and the possible decline in other cognitive functions
point to the importance of considering repeated neurocognitive
assessments as standard follow-up procedures for this group.
4.5 | Diagnostic overshadowing?
Recently, the term “diagnostic overshadowing” was used to describe
the underdiagnoses of comorbid psychiatric conditions in children
with severe neurological diseases (Hendriksen, Peijnenborgh,
Aldenkamp, & Vles, 2015). The authors suggested that more obvious
and important somatic features may overshadow a comorbid ADHD.
In Norway HT-1 was not included in the mandatory screening pro-
gram for newborns until 2012. Thus, few of the participants in this
study were recognized before presenting with serious symptoms. One
hypothesis may be that a delayed diagnosis contributes to diagnostic
overshadowing, as several of the parents probably have gone through
considerable strain before the diagnosis was settled. If the main focus
has been on survival of the child, diffuse symptoms as inattentiveness
may have been overlooked or neglected. If we assume that this possi-
ble bias is constant in the group, the relative differences between
reported problems might still be valid. Paradoxically, underdiagnosing
or overlooking impairing symptoms of ADHD may be especially harm-
ful to individuals who are dependent on strict treatment-regimes for
their medical condition, because of the unstructured lifestyle that
sometimes accompanies untreated ADHD. Therefore, early identifica-
tion of ADHD and treatment in medical conditions like HT-1 is impor-
tant from a lifetime-perspective, as this may also improve prognosis
for the medical condition itself. This has been demonstrated in adoles-
cents with type 1 diabetes, where poor metabolic control was found
in patients with undiagnosed ADHD (Nylander, Lindstrom, Khalifa, &
Fernell, 2018).
5 | CONCLUSION
NMDs, such as HT-1, constitute a large group of conditions that are
often containable with early clinical intervention, but still present life-
long difficulties and high societal costs. The long-term consequences
of treatments, despite their beneficial short-term effects should also
be investigated. This study suggests that there may be similar biologi-
cal mechanisms behind the cognitive difficulties seen in PKU, ADHD
and HT-1. In clinical settings, the impaired dopamine synthesis due to
substrate inhibition in treated HT-1 may be compensated for by stan-
dard ADHD medication, such as methylphenidate or amphetamine.
Similarly, the reduced serotonin synthesis may be counteracted by
tryptophan supplementation. Thorough assessment of ADHD and
monitoring of side-effects in accordance with clinical guidelines is
required for treatment with stimulants. In future studies, comparisons
of PKU and HT-1, in addition to other metabolic disorders influencing
similar biological pathways, will hopefully provide more insights into
possible shared pathophysiological mechanisms and how these affect
their treatment.
5.1 | Strengths and limitations
The main limitation of this study is the small number of participants,
which reflects the low prevalence of HT-1. Despite the limited sam-
ple, strong correlations were obtained. Still, replication studies and
studies with larger samples are needed.
The present results only show a correlation between inattentive-
ness and tyrosine levels, whereas causality may go both ways, as inat-
tentiveness also could lead to difficulties in managing diet (similar to
the Nylander et al. study of diabetes). However, if this was the case in
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this study, more general difficulties with executive functioning should
be suspected in patients with the highest levels of tyrosine.
We only used parent versions of questionnaires to obtain data,
and ideally information from teachers should also have been available.
In future studies, a complete assessment of ADHD in HT-1-patients
would give a more accurate picture of the prevalence of ADHD in this
group. A psychiatric diagnostic interview should also be part of such
an assessment. However, using dimensional data, as in this study, may
give important information about relationships between symptoms of
ADHD and biological measures, in addition to capturing the dimen-
sional nature of this psychiatric condition. Ideally, in future studies
both categorical and dimensional data should therefore be obtained. It
also may be of interest to collect experimental neuropsychological
data, especially because of the possible “diagnostic overshadowing”
and underreporting of symptoms. However, questionnaires could be
more valid than test results when assessing daily functioning and
predicting job performance (Barkley & Murphy, 2010). In further stud-
ies, a combination of questionnaires and neuropsychological tests
may be preferable, as they measure different aspects of
neurocognitive functioning (Barkley & Murphy, 2010). IQ should also
be measured to aquire more knowledge about the etiology behind the
different aspects of cognitive functioning in HT-1.
We did not measure tyrosine concentrations, or rates of mono-
amine synthesis directly in nerve terminal in relevant brain tissues in
the affected patients. Although a strong correlation has previously
been reported between plasma levels of tyrosine and its concentra-
tion in cerebrospinal fluid in HT-1 patients (Thimm et al., 2011), a
recent magnetic resonance spectroscopy study on PKU patients indi-
cated a large concentration gradient between blood and brain (poste-
rior cingulate gyrus and perventricular white matter) levels of
phenylalanine and tyrosine (Waisbren et al., 2017). Still, the effective
subcellular concentration of amino acids in relevant compartments of
monoaminergic neurons in these patients is not known. Furthermore,
while this study focused on effects on monoamine synthesis,
nitisinone treated HT-1 patients may have other biochemical distur-
bances that also may affect brain functions.
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